Revolutionizing Precision Heart Care

Learn more about the Heartflow Analysis

Bringing together human ingenuity and advanced technology to help combat heart disease, the #1 cause of death.

HeartFlow’s non-invasive personalized cardiac test provides unprecedented visualization of each patient’s coronary arteries, enabling physicians to create more effective treatment plans for their patients.

AI-Powered Algorithms

Analyst Verified

Taking innovation to heart

At the heart of our mission is a commitment to making cardiovascular care easier for doctors and safer for patients. Physicians get the critical information they need without the added risks and costs of an invasive procedure.

0 %

of the top 50 US heart hospitals have adopted HeartFlow

0 %

US commercial lives covered

Strength in Numbers


2x more likely to identify disease than other tests1

40% reduction in layered, repeat testing2

83% of unnecessary coronary angiograms cancelled3


Long-term studies with data out to 5 years

500+ Peer-Reviewed Publications

170,000+ trial and real-world patients

Strength in Numbers



2x more likely to identify
disease than other tests1

40% reduction in layered,
repeat testing2

83% of unnecessary coronary angiograms cancelled3

Long-term studies with
data out to 5 years

500+ Peer-Reviewed

100,000+ trial and
real-world patients

Strength in Numbers

HeartFlow will transform
the way we practice cardiology.

Kavitha Chinnaiyan, M.D.,
Dir. of Cardiac Imaging Research,
William Beaumont Hospital

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Jane Doe
Testimonial Giver

Contact Us

* Required Fields


  1. Nørgaard, et al. Euro J Radiol 2015. Incl. Jung, et al. Euro Heart J 2008.
    Melikian, et al. JACC Cardiovasc Interv 2010. Koo, et al. JACC 2011.
    Min, et al. J Am Med Assoc 2012. Nørgaard, et al. JACC 2014.
    Danad, et al. JAMA Cardiol 2017. Driessen, et al. JACC 2019.
  2. Curzen, et al. FORECAST trial presented at TCT Connect 2020.
  3. Douglas, et al. J Am Coll Cardiol 2016

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.